submitted on October 5, 2001 did not comply with the requirements of 37 CFR § 1.822. In particular, the Notice to Comply stated that where field <213> "Organism" response is either "Artificial Sequence" or "Unknown," the Sequence Listing must include a comment in field <223>.

Applicants respond as follows:

- 1. Applicants hereby provide a substitute computer readable form (CRF) copy of the amended "Sequence Listing" on diskette (enclosed), where each sequence that lists the source organism as "Artificial Sequence" includes an additional comment field <223> that reads "Artificial sequence is synthesized."
- 2. Applicants hereby provide a substitute paper copy corresponding to the substitute "Sequence Listing" (enclosed).
- 3. Applicants have requested that the specification be amended to enter the contents of the "Sequence Listing" into the specification, as set forth above under AMENDMENT.
- 4. Applicants hereby state that the content of the paper and computer readable copies of the "Sequence Listing" are the same, and that they include no new matter.

Applicants have assumed that their previously requested amendments to the specification and claims to identify each peptide sequence of the instant application with respect to the "Sequence Listing" have been appropriately entered into the application. If not,

Applicants request that the undersigned attorney be informed so that an appropriate amendment may be submitted.

Applicants believe that they have fully complied with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. However, if the Examiner has any questions, or if a telephone interview would in any way advance prosecution of this application, the Examiner is urged to contact the undersigned attorney.

CERTIFICATE OF MAILING

I hereby certify that this correspondence, the diskette with Sequence Listing, and a paper copy of the Sequence Listing are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on February 11, 2002.

Shannon R. Verboort

Respectfully submitted,

KOLISCH, HARTWELL, DICKINSON, McCORMACK & HEUSER

James R. Abney

Registration No. 42,253

520 S.W. Yamhill Street, Suite 200

Portland, Oregon 97204

Telephone: (503) 224-6655 Facsimile: (503) 295-6679 Attorney for Applicant

Our Docket No.: LJL 354B

COPY OF PAPERS ORIGINALLY FILED

February 11, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Dated: February 11, 2002

WEI HUANG, MERL F. HOEKSTRA, SANDRA K. LEE, NICHOLAS CAIRNS, LAWRENCE M. KAUVAR, and J. RICHARD SPORTSMAN

Serial No.

09/596,444

Examiner G. Gabel

RECEIVED

Filed

June 19, 2000

Group Art Unit 1645

MAR - 6 2002

For

PHOSPHORYLATION ASSAYS

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Transmitted herewith is an AMENDMENT for filing in the above-identified application:

Enclosed are also:

X Diskette with Sequence Listing.

Paper copy of Sequence Listing.

PATENT TRADEMARK OFFICE

No additional fee is required.

The fee has been calculated as shown below Claims as Amended **SMALL ENTITY**

(1)	(2) Claims remaining	(3) (4) Highest number previously paid for		(5) Present extra		(6)	(7) Additional fee	
	after amendment					Rate		
Total		,						
Claims	. 46	Minus	46	0	\$	9.00	= \$	00.00
Independer	nt							
Claims	09	Minus	09	. 0	\$	42.00	= \$	00.00
		T	his addit	ional fe	e	for		
		t	his amend	ment			\$	00.00

<u>X</u> Please charge any additional fees or credit overpayment to Deposit Account No. 11-1540. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KOLISCH, HARTWELL, DICKINSON,

McCORMACK & HEUSER

Registration No. 42,253

James R. Abney

Customer No. 23581

520 S.W. Yamhill Street, Suite 200

Portland, Oregon 97204

Telephone: (503)224-6655 Facsimile: (503)295-6679 Attorney for Applicants

JRA:srv **Enclosures**

· · · · · · · · · · · · · · · · · · ·		ORIGINALI ELED	
FED. 2 8 2002 on	Application N .	Applicant(s)	
Notice to Comply	09/596,444 Examin r	HUANG et al.	
	Gabel	1641	
OTICE TO COMPLY WITH REQU	JIREMENTS FO	R PATENT APPLICATIONS	

NC CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

th	he nucleotide and/or amino acid sequence disclosure contained in this application does not comply with se requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
\p ☑	plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
3	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
3	A statement that the content of the paper and computer readable copies are the same and the

aper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY